Loading Sign Up for
Dosing
Reminders Loading

Indication

NGENLA is a prescription product for the treatment of growth failure in children 3 years of age and older who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).

The Pfizer Bridge Program can support you in several ways
The Pfizer Bridge Program® can support you in several ways
Did you know?
NGENLA is covered by Express Scripts, Cigna, and more!

The program offers many support services including a Patient Care Consultant (PCC) who will work directly with your doctor, insurance company, and pharmacy to help your child get started on NGENLA as soon as possible. 
The program also provides the following support options:

Provides eligible, commercially insured patients with copay program enrollment

Device training

(in-home or virtual) by an experienced nurse

Assists with understanding the insurance process

Arranges for the first NGENLA shipment from the pharmacy and addresses issues that may lead to pharmacy delays or treatment interruptions

Getting started with the Pfizer Bridge Program

1.  
Your doctor prescribes NGENLA

Your healthcare provider will send your child’s prescription to a specialty pharmacy of their choosing or one required by your insurance plan. They may also choose to enroll your child in the Pfizer Bridge Program.
2. Your doctor enrolls your child in the Pfizer Bridge Program

Once you've been prescribed NGENLA, your doctor will complete an enrollment form and fax it to the Pfizer Bridge Program. You'll need to sign some important consents to complete the Pfizer Bridge Program enrollment process.

Note: If you signed these forms in your healthcare provider’s office, no action needed

Complete your enrollment
3.    
Work with our Pfizer 
Bridge Program Team

Once enrolled, you'll receive a call within 1 business day to welcome you into the program. This call will come from 1-800-645-1280, so be sure to save this number as the Pfizer Bridge Program in your contacts. We can help you understand your insurance coverage, navigate prior-authorization processes, 
and get connected with the appropriate specialty pharmacy, device training, and other support resources.

Complete your enrollment
Let's get started! The Pfizer Bridge Program is here to support your treatment journey with NGENLA. Here are some key steps you can expect:Prescribed NGENLA

Once you and your child's doctor determine that NGENLA is the right treatment, the doctor will prescribe the therapy.

 Pfizer Bridge Program Enrollment Form

You and your child's doctor will then complete the Pfizer Bridge Program Enrollment Form. A PCC, who is part of the Pfizer Bridge Program, will contact you following your enrollment. Watch for a call from 1-800-645-1280.

 Benefits Verification

Your child's doctor or the PCC will contact your insurance plan to confirm the growth hormone products available to your child and review the information with you.

 Prior Authorization Submission

Prescription drug plans (“plan”) often require your child's doctor to get approval or prior authorization before your child can be treated with NGENLA.

 Insurance Decision

Your plan will review the information submitted by your child's doctor and either approve or deny your child's prescription. Your child's doctor or the PCC will contact you with the plan’s decision. If your child's prescription is denied, the Pfizer Bridge Program can provide information on appeals requirements.

 Receive NGENLA

A specialty pharmacy will send NGENLA directly to your home. Your PCC can share the specialty pharmacy information with you, assist with coordinating medication shipments, and help with any medication or device issues that may arise.

 Device Training and Education

The Pfizer Bridge Program can help arrange in-home or virtual device training by an experienced nurse. View demonstration videos here. You can also contact the device support hotline at 1-800-645-1280 to speak with an experienced professional.

 Reauthorization

Plans may require your child to be reapproved to continue growth hormone treatment. Your PCC will contact you to ensure there is no lapse in your child's NGENLA treatment. 
Be sure to attend all scheduled doctor's appointments to prevent any delays in reauthorization.
For more information,
call 1-800-645-1280,
M-F 9-7 ET

Important Safety Information & Use

COLLapSE

IMPORTANT SAFETY

INFORMATION & USE
INDICATION
NGENLA is a prescription product for the treatment of growth failure in children 3 years of age and older who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).   
IMPORTANT SAFETY INFORMATION
  • Growth hormone should not be used in children after the growth plates have closed.
  • Growth hormone should not be used in children with some types of eye problems
    caused by diabetes (diabetic retinopathy).
  • Growth hormone should not be used in children who have cancer or other tumors.
  • Growth hormone should not be used in children who are critically ill because of some
    types of heart or stomach surgery, trauma, or breathing (respiratory) problems.
  • Growth hormone should not be used in children with Prader-Willi syndrome who are
    very overweight or have breathing problems including sleep apnea.
  • NGENLA should not be used by children who have had an allergic reaction to
    somatrogon-ghla or any of the ingredients in NGENLA. Look for prompt medical
    attention in case of an allergic reaction.
  • Some children have developed diabetes mellitus while taking growth hormone. Dosages
    of diabetes medicines may need to be adjusted during treatment with NGENLA.
    Children should be watched carefully if NGENLA is given along with glucocorticoid
    therapy and/or other drugs that are processed by the body in the same way.
  • In childhood cancer survivors, treatment with growth hormone may raise the likelihood
    of a new tumor, particularly some benign (non-cancerous) brain tumors. This likelihood
    may be higher in children who were treated with radiation to the brain or head. Your
    child’s health care provider will need to check your child for a return of cancer or a
    tumor.
  • Children treated with growth hormone have had increased pressure in the brain. If your
    child has headaches, eye problems, nausea (feeling like you are going to be sick), or
    vomiting, contact your child’s health care provider.
  • NGENLA may decrease thyroid hormone levels. Decreased thyroid hormone levels may
    change how well NGENLA works. Your child’s health care provider will do blood tests to
    check your child’s hormone levels.
  • Children treated with growth hormone should be checked regularly for low serum
    cortisol levels and/or the need to increase the dose of the glucocorticoids they are
    taking.
  • In children experiencing fast growth, curvature of the spine may develop or worsen. This
    is also called scoliosis. Children with scoliosis should be checked regularly to make sure
    their scoliosis does not get worse during their growth hormone therapy.
  • Use a different area on the body for each injection. This can help to avoid skin problems
    such as lumpiness or soreness.
  • Growth hormone treatment may cause serious and constant stomach (abdominal) pain.
    This could be a sign of pancreatitis. Tell your child’s health care provider if your child has
    any new stomach (abdominal) pain.
  • In studies of NGENLA in children with GHD, side effects included injection site reactions
    such as pain, swelling, rash, itching, or bleeding. Other side effects were the common
    cold, headache, fever (high temperature), low red blood cells (anemia), cough, vomiting,
    decreased thyroid hormone levels, stomach pain, rash, or throat pain.
  • A health care provider will help you with the first injection. He or she will also train you
    on how to inject NGENLA.
  • Rx only

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

© 2025 Pfizer Inc. All rights reserved.
PP-SMT-USA-0429